Other multifunctional kinase inhibitors that may be effective therapeutic agents for ovarian cancer include pazopanib (targets VEGFR, PDGFR, FGFR, and KIT), sunitinib (targets VEGFR, PDGFR, FLT3, and KIT), and sorafenib (targets VEGFR, PDGFR, and RAF kinases) (101). This evidence concerns the gene KDR and ovarian cancer.